See related Renagel tab[磷能解 錠] information |
|
製造商 |
Chugai |
代理/經銷商 |
Chugai |
成份 |
Sevelamer HCl |
適應症 |
Reduction of serum phosphorus in patients with end-stage renal disease (ESRD) on hemodialysis. |
用量 |
Patients not taking a phosphate binder Initially 800-1600 mg with each meal based on serum phosphorus level. Patients switching from Ca acetate Use equivalent doses (mg for mg) of Renagel cap & Ca acetate i.e. 1 tab (667 mg) Ca acetate to 1 tab (800 mg) Renagel. |
過量 |
View Renagel[磷能解] overdosage for action to be taken in the event of an overdose. |
用法 |
Should be taken with food (Swallow whole, do not chew/crush.). |
美國食品藥物管理局之懷孕等級 |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
禁忌 |
Hypophosphatemia or bowel obstruction. |
注意事項 |
Patients with dysphagia, swallowing disorders, severe GI motility disorders or major GIT surgery. Monitor serum Ca, bicarbonate & Cl levels. |
不良反應 |
GI disturbances, nasopharyngitis, bronchitis, upper respiratory tract infection, pain in limb, arthralgia, back pain, pruritus, dyspnea, cough, hypertension, headache, pyrexia.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
交互作用 |
Administer other oral medications at least 1 hr before or 3 hr after Renagel. Caution when coadministered with anti-arrhythmics & anti-seizure medications.
View more drug interactions with Renagel[磷能解] |
儲存 |
View Renagel[磷能解] storage conditions for details to ensure optimal shelf-life. |
描述 |
View Renagel[磷能解] description for details of the chemical structure and excipients (inactive components). |
作用 |
View Renagel[磷能解] mechanism of action for pharmacodynamics and pharmacokinetics details. |
本商品之市售規格 |
劑型 |
包裝 |
圖片 |
Renagel 錠劑 |
Renagel 400 mg x 50's |
Renagel 800 mg x 180's |
|
|
|
Manufacturer: |
Chugai |
Distributor: |
Chugai |
|
|
|
|